Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

YOU WONT BELIEVE: Trisalus life sciences q1 earnings call highlights | Mind Blowing Facts

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.

President and Chief Executive Officer Mary Szela said the company’s first-quarter results reflected the “deliberate cost of a build-out phase” as TriSalus expanded and realigned its sales organization to support growth in liver embolization and new applications for its Pressure-Enabled Drug Delivery, or PEDD, platform.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.